Influenza: Evolving Strategies in Treatment and Prevention

ABSTRACT

Influenza A and B are important causes of respiratory illness in all age groups. Influenza causes seasonal outbreaks globally, and (rarely) pandemics. In the United States, seasonal influenza epidemics account for > 200,000 hospitalizations and > 30,000 deaths annually. More than 90% of deaths are in the elderly. The toll is considerably higher during pandemics. Clinical features of influenza infection overlap with other respiratory pathogens (particularly viruses). The diagnosis is often delayed due to low suspicion and the limited use of specific diagnostic tests. Rapid diagnostic tests are widely available and allow detection of influenza antigen in respiratory secretions within 1 hour; however, sensitivity ranges from 40 to 80%. Currently, four drugs are available to treat or prevent influenza. These include the adamantanes (i.e., amantadine and rimantadine) and the neuraminidase inhibitors (i.e., oseltamivir and zanamivir). Adamantanes are active against influenza A but not influenza B. However, recent emergence of adamantane resistance has rendered these agents ineffective. Hence, adamantanes are not currently recommended in the United States. The neuraminidase inhibitors (NAIs) are effective in treating influenza A or B, and for prophylaxis in selected adults and children. Resistance to NAIs is rare, but influenza strains resistant to oseltamivir have been detected. Vaccines are the cornerstone of influenza control. Currently, trivalent inactivated vaccine (TIV) and live attenuated influenza vaccine (LAIV) are available. These agents reduce mortality and morbidity in high-risk patients (i.e., the elderly or patients with comorbidities), and expanding the use of vaccines to healthy children and adults reduces the incidence of influenza, pneumonia, and hospitalizations due to respiratory illnesses in the community.

KEYWORDS

Influenza A and B - epidemics - pandemics - adamantanes - neuraminidase inhibitors - vaccination

REFERENCES

• 1 Petric M, Comanor L, Petti C A. Role of the laboratory in diagnosis of influenza during seasonal epidemics and potential pandemics.  J Infect Dis. 2006;  194(Suppl 2) S98-S110
• 2 Bright R A, Medina M J, Xu X et al.. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern.  Lancet. 2005;  366 1175-1181
• 3 Nichol K L, Treanor J J. Vaccines for seasonal and pandemic influenza.  J Infect Dis. 2006;  194(Suppl 2) S111-S118
• 4 Neuzil K M, Zhu Y, Griffin M R et al.. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study.  J Infect Dis. 2002;  185 147-152
• 5 Chew F T, Doraisingham S, Ling A E, Kumarasinghe G, Lee B W. Seasonal trends of viral respiratory tract infections in the tropics.  Epidemiol Infect. 1998;  121 121-128
• 6 Sugawa N, Mitamura K, Yamazaki M et al.. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children.  Clin Infect Dis. 2007;  44 197-202
• 7 Kawai N, Ikematsu H, Iwaki N et al.. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season.  Clin Infect Dis. 2005;  40 1309-1316
• 8 Glezen W P, Couch R B. Interpandemic influenza in the Houston area, 1974-76.  N Engl J Med. 1978;  298 587-592
• 9 Fox J P, Cooney M K, Hall C E, Foy H M. Influenzavirus infections in Seattle families, 1975-1979, II: Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness.  Am J Epidemiol. 1982;  116 228-242
• 10 Thompson W W, Comanor L, Shay D K. Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease.  J Infect Dis. 2006;  194(Suppl 2) S82-S91
• 11 Thompson W W, Shay D K, Weintraub E et al.. Mortality associated with influenza and respiratory syncytial virus in the United States.  JAMA. 2003;  289 179-186
• 12 Osterholm M T. Preparing for the next pandemic.  N Engl J Med. 2005;  352 1839-1842
• 13 Johnson N P, Mueller J. Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic.  Bull Hist Med. 2002;  76 105-115
• 14 Rajagopal S, Treanor J. Pandemic (avian) influenza.  Semin Respir Crit Care Med. 2007;  28 159-170
• 15 Poehling K A, Edwards K M, Weinberg G A et al.. The underrecognized burden of influenza in young children.  N Engl J Med. 2006;  355 31-40
• 16 Whitley R J, Monto A S. Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents.  J Infect Dis. 2006;  194(Suppl 2) S133-S138
• 17 Whimbey E, Elting L S, Couch R B et al.. Influenza A virus infections among hospitalized adult bone marrow transplant recipients.  Bone Marrow Transplant. 1994;  13 437-440
• 18 Nichols W G, Guthrie K A, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy.  Clin Infect Dis. 2004;  39 1300-1306
• 19 Kim Y-J, Boeckh M, Englund J A. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection.  Semin Respir Crit Care Med. 2007;  28 222-242
• 20 Ison M G, Gubareva L V, Atmar R L, Treanor J, Hayden F G. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series.  J Infect Dis. 2006;  193 760-764
• 21 Murata Y, Walsh E, Falsey A. Pulmonary complications of inter-pandemic influenza A in hospitalized patients.  J Infect Dis. 2007;  195 1029-1037
• 22 Kobasa D, Takada A, Shinya K et al.. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus.  Nature. 2004;  431 703-707
• 23 Louria D B, Blumenfeld H L, Ellis J T, Kilbourne E D, Rogers D E. Studies on influenza in the pandemic of 1957-1958, II: Pulmonary complications of influenza.  J Clin Invest. 1959;  38(1 Part 2) 213-265
• 24 O'Brien K L, Walters M I, Sellman J et al.. Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection.  Clin Infect Dis. 2000;  30 784-789
• 25 Fainstein V, Musher D M, Cate T R. Bacterial adherence to pharyngeal cells during viral infection.  J Infect Dis. 1980;  141 172-176
• 26 Edelen J S, Bender T R, Chin T D. Encephalopathy and pericarditis during an outbreak of influenza.  Am J Epidemiol. 1974;  100 79-84
• 27 Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children.  Clin Infect Dis. 2003;  36 299-305
• 28 Morishima T, Togashi T, Yokota S et al.. Encephalitis and encephalopathy associated with an influenza epidemic in Japan.  Clin Infect Dis. 2002;  35 512-517
• 29 Starko K M, Ray C G, Dominguez L B, Stromberg W L, Woodall D F. Reye's syndrome and salicylate use.  Pediatrics. 1980;  66 859-864
• 30 Belay E D, Bresee J S, Holman R C, Khan A S, Shahriari A, Schonberger L B. Reye's syndrome in the United States from 1981 through 1997.  N Engl J Med. 1999;  340 1377-1382
• 31 Englund J A, Champlin R E, Wyde P R et al.. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults.  Clin Infect Dis. 1998;  26 1418-1424
• 32 Hirschhorn L R, McIntosh K, Anderson K G, Dermody T S. Influenzal pneumonia as a complication of autologous bone marrow transplantation.  Clin Infect Dis. 1992;  14 786-787
• 33 Ljungman P, Andersson J, Aschan J et al.. Influenza A in immunocompromised patients.  Clin Infect Dis. 1993;  17 244-247
• 34 Apalsch A M, Green M, Ledesma-Medina J, Nour B, Wald E R. Parainfluenza and influenza virus infections in pediatric organ transplant recipients.  Clin Infect Dis. 1995;  20 394-399
• 35 Neuzil K M, Reed G W, Mitchel E F, Simonsen L, Griffin M R. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women.  Am J Epidemiol. 1998;  148 1094-1102
• 36 O'Brien M A, Uyeki T M, Shay D K et al.. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children.  Pediatrics. 2004;  113(3 Pt 1) 585-593
• 37 Grijalva C G, Craig A S, Dupont W D et al.. Estimating influenza hospitalizations among children.  Emerg Infect Dis. 2006;  12 103-109
• 38 Izurieta H S, Thompson W W, Kramarz P et al.. Influenza and the rates of hospitalization for respiratory disease among infants and young children.  N Engl J Med. 2000;  342 232-239
• 39 Meltzer M I, Neuzil K M, Griffin M R, Fukuda K. An economic analysis of annual influenza vaccination of children.  Vaccine. 2005;  23 1004-1014
• 40 Neuzil K M, Mellen B G, Wright P F, Mitchel Jr E F, Griffin M R. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.  N Engl J Med. 2000;  342 225-231
• 41 Bhat N, Wright J G, Broder K R et al.. Influenza-associated deaths among children in the United States, 2003-2004.  N Engl J Med. 2005;  353 2559-2567
• 42 Walsh E E, Cox C, Falsey A R. Clinical features of influenza A virus infection in older hospitalized persons.  J Am Geriatr Soc. 2002;  50 1498-1503
• 43 Uyeki T M. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza.  Pediatr Infect Dis J. 2003;  22 164-177
• 44 Weinberg G A, Erdman D D, Edwards K M et al.. Superiority of reverse-transcription polymerase chain reaction to conventional viral culture in the diagnosis of acute respiratory tract infections in children.  J Infect Dis. 2004;  189 706-710
• 45 Bonner A B, Monroe K W, Talley L I, Klasner A E, Kimberlin D W. Impact of the rapid diagnosis of influenza on physician decision-making and patient management in the pediatric emergency department: results of a randomized, prospective, controlled trial.  Pediatrics. 2003;  112 363-367
• 46 Sharma V, Dowd M D, Slaughter A J, Simon S D. Effect of rapid diagnosis of influenza virus type a on the emergency department management of febrile infants and toddlers.  Arch Pediatr Adolesc Med. 2002;  156 41-43
• 47 Poehling K A, Griffin M R, Dittus R S et al.. Bedside diagnosis of Influenzavirus infections in hospitalized children.  Pediatrics. 2002;  110(1 Pt 1) 83-88
• 48 Couch R B. Prevention and treatment of influenza.  N Engl J Med. 2000;  343 1778-1787
• 49 Moscona A. Neuraminidase inhibitors for influenza.  N Engl J Med. 2005;  353 1363-1373
• 50 Wang C, Takeuchi K, Pinto L H, Lamb R A. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block.  J Virol. 1993;  67 5585-5594
• 51 Bright R A, Shay D K, Shu B, Cox N J, Klimov A I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States.  JAMA. 2006;  295 891-894
• 52 High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents-United States, 2005-06 influenza season.  MMWR Morb Mortal Wkly Rep. 2006;  55 44-46
• 53 Smith N M, Bresee J S, Shay D K, Uyeki T M, Cox N J, Strikas R A. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2006;  55(RR-10) 1-42
• 54 Monto A S, Ohmit S E, Hornbuckle K, Pearce C L. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes.  Antimicrob Agents Chemother. 1995;  39 2224-2228
• 55 Younkin S W, Betts R F, Roth F K, Douglas Jr R G. Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine.  Antimicrob Agents Chemother. 1983;  23 577-582
• 56 Dolin R, Reichman R C, Madore H P, Maynard R, Linton P N, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection.  N Engl J Med. 1982;  307 580-584
• 57 Brady M T, Sears S D, Pacini D L et al.. Safety and prophylactic efficacy of low-dose rimantadine in adults during an influenza A epidemic.  Antimicrob Agents Chemother. 1990;  34 1633-1636
• 58 Reuman P D, Bernstein D I, Keefer M C, Young E C, Sherwood J R, Schiff G M. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A.  Antiviral Res. 1989;  11 27-40
• 59 Van Voris L P, Betts R F, Hayden F G, Christmas W A, Douglas Jr R G. Successful treatment of naturally occurring influenza A/USSR/77 H1N1.  JAMA. 1981;  245 1128-1131
• 60 Monto A S, Gunn R A, Bandyk M G, King C L. Prevention of Russian influenza by amantadine.  JAMA. 1979;  241 1003-1007
• 61 Patriarca P A, Kater N A, Kendal A P, Bregman D J, Smith J D, Sikes R K. Safety of prolonged administration of rimantadine hydrochloride in the prophylaxis of influenza A virus infections in nursing homes.  Antimicrob Agents Chemother. 1984;  26 101-103
• 62 Galbraith A W, Oxford J S, Schild G C, Watson G I. Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment: a controlled double-blind study.  Lancet. 1969;  2 1026-1028
• 63 Hayden F G, Belshe R B, Clover R D, Hay A J, Oakes M G, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families.  N Engl J Med. 1989;  321 1696-1702
• 64 Keyser L A, Karl M, Nafziger A N, Bertino Jr J S. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients.  Arch Intern Med. 2000;  160 1485-1488
• 65 Weinstock D M, Zuccotti G. Adamantane resistance in influenza A.  JAMA. 2006;  295 934-936
• 66 Hall C B, Dolin R, Gala C L et al.. Children with influenza A infection: treatment with rimantadine.  Pediatrics. 1987;  80 275-282
• 67 Houck P, Hemphill M, LaCroix S, Hirsh D, Cox N. Amantadine-resistant influenza A in nursing homes: identification of a resistant virus prior to drug use.  Arch Intern Med. 1995;  155 533-537
• 68 Belshe R B, Burk B, Newman F, Cerruti R L, Sim I S. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance.  J Infect Dis. 1989;  159 430-435
• 69 Prud'homme I T, Zoueva O, Weber J M. Amantadine susceptibility in influenza A virus isolates: determination methods and lack of resistance in a Canadian sample, 1991-94.  Clin Diagn Virol. 1997;  8 41-51
• 70 Ilyushina N A, Govorkova E A, Webster R G. Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia.  Virology. 2005;  341 102-106
• 71 Rodriguez W J, Hall C B, Welliver R et al.. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial.  J Pediatr. 1994;  125 129-135
• 72 Knight V, McClung H W, Wilson S Z et al.. Ribavirin small-particle aerosol treatment of influenza.  Lancet. 1981;  2 945-949
• 73 Gilbert B E, Wilson S Z, Knight V et al.. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84.  Antimicrob Agents Chemother. 1985;  27 309-313
• 74 Oxford J, Balasingam S, Lambkin R. A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community.  J Antimicrob Chemother. 2004;  53 133-136
• 75 Cooper N J, Sutton A J, Abrams K R, Wailoo A, Turner D, Nicholson K G. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials.  BMJ. 2003;  326 1235
• 76 Boivin G, Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors.  Antiviral Res. 2002;  54 143-147
• 77 Freund B, Gravenstein S, Elliott M, Miller I. Zanamivir: a review of clinical safety.  Drug Saf. 1999;  21 267-281
• 78 Hayden F G, Belshe R, Villanueva C et al.. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis.  J Infect Dis. 2004;  189 440-449
• 79 McClellan K, Perry C M. Oseltamivir: a review of its use in influenza.  Drugs. 2001;  61 263-283
• 80 Hayden F G, Pavia A T. Antiviral management of seasonal and pandemic influenza.  J Infect Dis. 2006;  194(Suppl 2) S119-S126
• 81 Treanor J J, Hayden F G, Vrooman P S et al.. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.  JAMA. 2000;  283 1016-1024
• 82 Nicholson K G, Aoki F Y, Osterhaus A D et al.. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.  Lancet. 2000;  355 1845-1850
• 83 Aoki F Y, Macleod M D, Paggiaro P et al.. Early administration of oral oseltamivir increases the benefits of influenza treatment.  J Antimicrob Chemother. 2003;  51 123-129
• 84 Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.  Arch Intern Med. 2003;  163 1667-1672
• 85 Hedrick J A, Barzilai A, Behre U et al.. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial.  Pediatr Infect Dis J. 2000;  19 410-417
• 86 Bowles S K, Lee W, Simor A E et al.. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000.  J Am Geriatr Soc. 2002;  50 608-616
• 87 Nordstrom B L, Sung I, Suter P, Szneke P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir.  Curr Med Res Opin. 2005;  21 761-768
• 88 Whitley R J, Hayden F G, Reisinger K S et al.. Oral oseltamivir treatment of influenza in children.  Pediatr Infect Dis J. 2001;  20 127-133
• 89 Hayden F G, Atmar R L, Schilling M et al.. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.  N Engl J Med. 1999;  341 1336-1343
• 90 Welliver R, Monto A S, Carewicz O et al.. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial.  JAMA. 2001;  285 748-754
• 91 Monto A S, Rotthoff J, Teich E et al.. Detection and control of influenza outbreaks in well-vaccinated nursing home populations.  Clin Infect Dis. 2004;  39 459-464
• 92 Peters Jr P H, Gravenstein S, Norwood P et al.. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population.  J Am Geriatr Soc. 2001;  49 1025-1031
• 93 Rothberg M B, Bellantonio S, Rose D N. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy.  Ann Intern Med. 2003;  139(5 Pt 1) 321-329
• 94 Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group.  Lancet. 1998;  352 1877-1881
• 95 Monto A S, Pichichero M E, Blanckenberg S J et al.. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households.  J Infect Dis. 2002;  186 1582-1588
• 96 de Jong M D, Tran T T, Truong H K et al.. Oseltamivir resistance during treatment of influenza A (H5N1) infection.  N Engl J Med. 2005;  353 2667-2672
• 97 Hayden F G, Osterhaus A D, Treanor J J et al.. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of Influenzavirus infections. GG167 Influenza Study Group.  N Engl J Med. 1997;  337 874-880
• 98 Monto A S, Fleming D M, Henry D et al.. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections.  J Infect Dis. 1999;  180 254-261
• 99 Lalezari J, Campion K, Keene O, Silagy C. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials.  Arch Intern Med. 2001;  161 212-217
• 100 Kaiser L, Keene O N, Hammond J M, Elliott M, Hayden F G. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults.  Arch Intern Med. 2000;  160 3234-3240
• 101 Makela M J, Pauksens K, Rostila T et al.. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study.  J Infect. 2000;  40 42-48
• 102 Matsumoto K, Ogawa N, Nerome K et al.. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group.  Antivir Ther. 1999;  4 61-68
• 103 Monto A S, Robinson D P, Herlocher M L, Hinson Jr J M, Elliott M J, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial.  JAMA. 1999;  282 31-35
• 104 Hayden F G, Gubareva L V, Monto A S et al.. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group.  N Engl J Med. 2000;  343 1282-1289
• 105 Cass L M, Gunawardena K A, Macmahon M M, Bye A. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir.  Respir Med. 2000;  94 166-173
• 106 Gubareva L V, Kaiser L, Hayden F G. Influenza virus neuraminidase inhibitors.  Lancet. 2000;  355 827-835
• 107 McKimm-Breschkin J, Trivedi T, Hampson A et al.. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.  Antimicrob Agents Chemother. 2003;  47 2264-2272
• 108 Moscona A. Oseltamivir-resistant influenza?.  Lancet. 2004;  364 733-734
• 109 Moscona A. Oseltamivir resistance-disabling our influenza defenses.  N Engl J Med. 2005;  353 2633-2636
• 110 Brett A S, Zuger A. The run on Tamiflu-should physicians prescribe on demand?.  N Engl J Med. 2005;  353 2636-2637
• 111 Yen H L, Herlocher L M, Hoffmann E et al.. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.  Antimicrob Agents Chemother. 2005;  49 4075-4084
• 112 Stilianakis N I, Perelson A S, Hayden F G. Drug resistance and influenza pandemics.  Lancet. 2002;  359 1862-1863
• 113 Kiso M, Mitamura K, Sakai-Tagawa Y et al.. Resistant influenza A viruses in children treated with oseltamivir: descriptive study.  Lancet. 2004;  364 759-765
• 114 Beigel J H, Farrar J, Han A M et al.. Avian influenza A (H5N1) infection in humans.  N Engl J Med. 2005;  353 1374-1385
• 115 Le Q M, Kiso M, Someya K et al.. Avian flu: isolation of drug-resistant H5N1 virus.  Nature. 2005;  437 1108
• 116 Carr J, Ives J, Kelly L et al.. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.  Antiviral Res. 2002;  54 79-88
• 117 Ives J A, Carr J A, Mendel D B et al.. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.  Antiviral Res. 2002;  55 307-317
• 118 Gubareva L V, Matrosovich M N, Brenner M K, Bethell R C, Webster R G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus.  J Infect Dis. 1998;  178 1257-1262
• 119 Lee T H. Rationing influenza vaccine.  N Engl J Med. 2004;  351 2365-2366
• 120 Schwartz B, Hinman A, Abramson J et al.. Universal influenza vaccination in the United States: are we ready? Report of a meeting.  J Infect Dis. 2006;  194(Suppl 2) S147-S154
• 121 Schmidt A. Progress in respiratory virus vaccine development.  Semin Respir Crit Care Med. 2007;  28 243-252
• 122 Fukuda K, Kieny M P. Different approaches to influenza vaccination.  N Engl J Med. 2006;  355 2586-2587
• 123 Recommended composition of influenza virus vaccines for use in the 2004-2005 influenza season.  Wkly Epidemiol Rec. 2004;  79 88-92
• 124 Bridges C B, Thompson W W, Meltzer M I et al.. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial.  JAMA. 2000;  284 1655-1663
• 125 Ohmit S E, Victor J C, Rotthoff J R et al.. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines.  N Engl J Med. 2006;  355 2513-2522
• 126 Harper S A, Fukuda K, Uyeki T M, Cox N J, Bridges C B. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2005;  54(RR-8) 1-40
• 127 Small Jr P A, Bender B S. Vaccination against influenza in healthy adults.  N Engl J Med. 1996;  334 402-403 , author reply 3-4
• 128 Nichol K L, Lind A, Margolis K L et al.. The effectiveness of vaccination against influenza in healthy, working adults.  N Engl J Med. 1995;  333 889-893
• 129 Nichol K L. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.  Arch Intern Med. 2001;  161 749-759
• 130 Demicheli V, Rivetti D, Deeks J J, Jefferson T O. Vaccines for preventing influenza in healthy adults.  Cochrane Database Syst Rev. 2004;  (3) CD001269
• 131 Gross P A, Hermogenes A W, Sacks H S, Lau J, Levandowski R A. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature.  Ann Intern Med. 1995;  123 518-527
• 132 Ohmit S E, Arden N H, Monto A S. Effectiveness of inactivated influenza vaccine among nursing home residents during an influenza type A (H3N2) epidemic.  J Am Geriatr Soc. 1999;  47 165-171
• 133 Potter J, Stott D J, Roberts M A et al.. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients.  J Infect Dis. 1997;  175 1-6
• 134 Wilde J A, McMillan J A, Serwint J, Butta J, O'Riordan M A, Steinhoff M C. Effectiveness of influenza vaccine in health care professionals: a randomized trial.  JAMA. 1999;  281 908-913
• 135 Pearson M L, Bridges C B, Harper S A. Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2006;  55(RR-2) 1-16
• 136 Carman W F, Elder A G, Wallace L A et al.. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial.  Lancet. 2000;  355 93-97
• 137 Burls A, Jordan R, Barton P et al.. Vaccinating healthcare workers against influenza to protect the vulnerable-is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation.  Vaccine. 2006;  24 4212-4221
• 138 Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community.  Vaccine. 2002;  20 1831-1836
• 139 Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review.  Lancet. 2005;  366 1165-1174
• 140 Nichol K L, Margolis K L, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community.  N Engl J Med. 1994;  331 778-784
• 141 Fedson D S, Wajda A, Nicol J P, Hammond G W, Kaiser D L, Roos L L. Clinical effectiveness of influenza vaccination in Manitoba.  JAMA. 1993;  270 1956-1961
• 142 Foster D A, Talsma A, Furumoto-Dawson A et al.. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly.  Am J Epidemiol. 1992;  136 296-307
• 143 Arden N, Monto A S, Ohmit S E. Vaccine use and the risk of outbreaks in a sample of nursing homes during an influenza epidemic.  Am J Public Health. 1995;  85 399-401
• 144 Monto A S, Hornbuckle K, Ohmit S E. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study.  Am J Epidemiol. 2001;  154 155-160
• 145 Nichol K L, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly.  N Engl J Med. 2003;  348 1322-1332
• 146 Mullooly J P, Bennett M D, Hornbrook M C et al.. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization.  Ann Intern Med. 1994;  121 947-952
• 147 Nichol K L, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens.  Arch Intern Med. 1998;  158 1769-1776
• 148 Hak E, Buskens E, van Essen G A et al.. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study.  Arch Intern Med. 2005;  165 274-280
• 149 Nichol K L, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease.  Ann Intern Med. 1999;  130 397-403
• 150 Jefferson T, Smith S, Demicheli V, Harnden A, Rivetti A, Di Pietrantonj C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review.  Lancet. 2005;  365 773-780
• 151 Negri E, Colombo C, Giordano L, Groth N, Apolone G, La Vecchia C. Influenza vaccine in healthy children: a meta-analysis.  Vaccine. 2005;  23 2851-2861
• 152 Hurwitz E S, Haber M, Chang A et al.. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts.  JAMA. 2000;  284 1677-1682
• 153 Reichert T A, Sugaya N, Fedson D S, Glezen W P, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza.  N Engl J Med. 2001;  344 889-896
• 154 Piedra P A, Gaglani M J, Kozinetz C A et al.. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children.  Vaccine. 2005;  23 1540-1548
• 155 Monto A S, Davenport F M, Napier J A, Francis Jr T. Modification of an outbreak of influenza in Tecumseh, Michigan, by vaccination of schoolchildren.  J Infect Dis. 1970;  122 16-25
• 156 Heikkinen T, Ruuskanen O, Waris M, Ziegler T, Arola M, Halonen P. Influenza vaccination in the prevention of acute otitis media in children.  Am J Dis Child. 1991;  145 445-448
• 157 Weller S C, Mann N C. Influenza vaccination and acute otitis media in children.  Am J Dis Child. 1992;  146 1018-1019
• 158 Clements D A, Langdon L, Bland C, Walter E. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care.  Arch Pediatr Adolesc Med. 1995;  149 1113-1117
• 159 Belshe R B, Mendelman P M, Treanor J et al.. The efficacy of live attenuated, cold-adapted, trivalent, intranasal Influenzavirus vaccine in children.  N Engl J Med. 1998;  338 1405-1412
• 160 Podewils L J, Liedtke L A, McDonald L C et al.. A national survey of severe influenza-associated complications among children and adults, 2003-2004.  Clin Infect Dis. 2005;  40 1693-1696
• 161 Brownstein J S, Kleinman K P, Mandl K D. Identifying pediatric age groups for influenza vaccination using a real-time regional surveillance system.  Am J Epidemiol. 2005;  162 686-693
• 162 King Jr J C, Stoddard J J, Gaglani M J et al.. Effectiveness of school-based influenza vaccination.  N Engl J Med. 2006;  355 2523-2532
• 163 Jordan R, Connock M, Albon E et al.. Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence.  Vaccine. 2006;  24 1047-1062
• 164 Prevention and control of influenza: recommendations of the Immunization Practices Advisory Committee (ACIP).  MMWR Recomm Rep. 1990;  39(RR-7) 1-15
• 165 Influenza vaccination levels in selected states: Behavioral Risk Factor Surveillance System, 1987.  MMWR Morb Mortal Wkly Rep. 1989;  38 124, 9-33
• 166 Prevention and control of influenza, I: Vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 1994;  43(RR-9) 1-13
• 167 Bridges C B, Winquist A G, Fukuda K, Cox N J, Singleton J A, Strikas R A. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2000;  49(RR-3) 1-38 , quiz CE1-7
• 168 Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 1997;  46(RR-9) 1-25
• 169 Bridges C B, Fukuda K, Uyeki T M, Cox N J, Singleton J A. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Recomm Rep. 2002;  51(RR-3) 1-31
• 170 Hemingway C O, Poehling K A. Change in recommendation affects influenza vaccinations among children 6 to 59 months of age.  Pediatrics. 2004;  114 948-952
• 171 Arden N H. Control of influenza in the long-term-care facility: a review of established approaches and newer options.  Infect Control Hosp Epidemiol. 2000;  21 59-64
• 172 Estimated influenza vaccination coverage among adults and children: United States, September 1, 2004-January 31, 2005.  MMWR Morb Mortal Wkly Rep. 2005;  54 304-307
• 173 Nichol K L, Margolis K L, Lind A et al.. Side effects associated with influenza vaccination in healthy working adults: a randomized, placebo-controlled trial.  Arch Intern Med. 1996;  156 1546-1550
• 174 Margolis K L, Nichol K L, Poland G A, Pluhar R E. Frequency of adverse reactions to influenza vaccine in the elderly: a randomized, placebo-controlled trial.  JAMA. 1990;  264 1139-1141
• 175 James J M, Zeiger R S, Lester M R et al.. Safe administration of influenza vaccine to patients with egg allergy.  J Pediatr. 1998;  133 624-628
• 176 Hurwitz E S, Schonberger L B, Nelson D B, Holman R C. Guillain-Barré syndrome and the 1978-1979 influenza vaccine.  N Engl J Med. 1981;  304 1557-1561
• 177 Schonberger L B, Bregman D J, Sullivan-Bolyai J Z et al.. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977.  Am J Epidemiol. 1979;  110 105-123
• 178 Marks J S, Halpin T J. Guillain-Barré syndrome in recipients of A/New Jersey influenza vaccine.  JAMA. 1980;  243 2490-2494
• 179 Lasky T, Terracciano G J, Magder L et al.. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.  N Engl J Med. 1998;  339 1797-1802
• 180 Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention.  MMWR Recomm Rep. 1998;  47(RR-6) 1-26
• 181 Nichol K L, Mendelman P M, Mallon K P et al.. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.  JAMA. 1999;  282 137-144